Endometrioid adenocarcinoma arising from adenomyosis: Report and immunohistochemical analysis of an unusual case

Pathology International

Volumn 51, Issue 4, 2001, Pages 308-313

  Sasaki, Toshiki ^a,d   Sugiyama, Tatsuo ^a   Nanjo, Hiroshi ^a,b   Hoshi, Naoto ^a,b   Murakami, Masayo ^a   Sugita, Akihiro ^a   Takahashi, Masato ^c   Kawamura, Koichi ^a   Ono, Iwao ^a   Masuda, Hirotake ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AKITA UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^d NAKADORI GENERAL HOSPITAL   (Japan)

Author keywords

Adenomyosis; Endometrial smear cytology; Endometrioid adenocarcinoma; Immunohistochemistry; Ki 67 antigen; P53 oncoprotein

Indexed keywords

CARBOPLATIN; KI 67 ANTIGEN; PACLITAXEL; PROTEIN P53;

ADENOMYOSIS; ADULT; ARTICLE; CASE REPORT; CYTOLOGY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; SMEAR;

ADENOCARCINOMA; ENDOMETRIAL NEOPLASMS; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED;

EID: 0035008629     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2001.01200.x     Document Type: Article

References (24)

1. Giammalvo JT, Kaplan K. The incidence of endometriosis interna in 120 cases of carcinoma of the endometrium, Am. J. Obstet. Gynecol. 1958; 75: 161-166.
2. Marcus CC. Relationship of adenomyosis uteri to endometrial hyperplasia and endometrial carcinoma. Am. J. Obstet. Gynecol 1961; 82: 408-416.
3. Hernandez E, Woodruff JD. Endometrial adenocarcinoma arising in adenomyosis. Am. J. Obstet. Gynecol. 1980; 138: 827-832.
4. Colman HI, Rosenthal AH. Carcinoma developing in areas of adenomyosis. Obstet. Gynecol. 1959; 14: 342-348.
5. Vihko R, Janne O, Kauppila A. Steroid receptors in normal, hyperplastic and malignant human endometrium. Ann. Clin. Res. 1980; 12: 208-215.
6. Nyholm HCJ, Nielsen AL, Lyndrup J, Norup P, Thorpe SM. Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlations with stage and other clinicopathologic features. Am. J. Obstet. Gynecol. 1992; 167: 1334-1342.
7. Chambers JT, MacLusky N, Eisenfield A, Kohorn EI, Lawrence R, Schwartz PE. Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol. Oncol. 1988; 31: 65-77.
8. Ehrlich CE, Young PCM, Stehman FB, Sutton GP, Alford WM. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am. J. Obstet. Gynecol. 1988; 158: 796-807.
9. Palmer DC, Muir IM, Alexander AI, Cauchi M, Bennett RC, Quinn MA. The prognostic Importance of steroid receptors in endometrial carcinoma. Obstet. Gynecol. 1988; 72: 388-393.
10. Chambers JT, Carcangiu ML, Voynick IM, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content In 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival. Am. J. Clin. Pathol. 1990; 94: 255-260.
11. Pertschuk LP, Masood S, Simone J, Feldman JG, Fruchter RG, Axiotis CA, Greene GL. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol. Oncol. 1996; 63: 28-33.
12. Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol. Oncol. 1998; 69: 220-225.
13. Pertschuk LP, Beddoe AM, Gorelic LS, Shain SA. Immunocytochemical assay of estrogen receptors In endometrial carcinoma with monoclonal antibodies: comparison with biochemical assay. Cancer 1986; 57: 1000-1004.
14. Soper JT, Segreti EM, Novotny DB, Mutch D, Creasman WT, McCarty KS Jr. Estrogen and progesterone receptor content of endometrial carcinomas: comparison of total tissue versus cancer component analysis. Gynecol. Oncol. 1990; 36:363-368.
15. Gehrig PA, Le LV, Olatidoye B, Geradts J, Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer 1999; 86: 2083-2089.
16. Mortel R, Zaino R, Satyaswaroop PG. Heterogeneity and progesterone-receptor distribution in endometrial adenocarcinoma. Cancer 1984; 53: 113-116.
17. Taskin M, Lallas TA, Shevchuk M, Barber HRK, p53 expression in adenomyosis in endometrial carcinoma patients. Gynecol. Oncol. 1996; 62: 241-246.
18. Niwa K, Murase T, Morishita S, Hashimoto M, Itoh N, Tamaya T. p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status. Cancer Detect. Prev. 1999; 23: 147-154.
19. Athanassiadou P, Petrakakou E, Liossi A, Nakopoulou L, Zerva C, Dimopoulos A, Athanassiades P. Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium. Acta Cytol. 1999; 43: 1039-1044.
20. Yamauchi N, Sakamoto A, Uozaki H, Iihara K, Machinami R. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 In relation to expression of sex steroid receptor and proliferative activity. Int. J. Gynecol. Pathol. 1996; 15: 202-208.
21. Salvesen HB, Iversen OE, Akslen LA. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin. Cancer Res. 1998; 4: 2779-2785.
22. Lu QL, Poulsom R, Wong L, Hanby AM, bcl-2 expression in adult and embryonic non-haematopoietic tissues. J. Pathol. 1993; 169: 431-437.
23. Gompel A, Sabourin JC, Martin A, Yaneva H, Audouin J, Decroix Y, Poitout P. bcl-2 expression in normal endometrium during the menstrual cycle. Am. J. Pathol. 1994; 144: 1195-1202.
24. Henderson GS, Brown KA, Perkins SL, Abbott TM, Clayton F. bcl-2 is down-regulated in atypical endometrial hyperplasia and adenocarcinoma. Mod. Pathol. 1996; 9: 430-438.